Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs CF Industries Holdings, Inc. (CF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs CF Industries Holdings, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while CF Industries Holdings, Inc. trades at $117.6 (market cap $17.96B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.2× CF Industries Holdings, Inc.'s market cap, and CF Industries Holdings, Inc. pays a 2.05% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CF | |
|---|---|---|
Market Cap | $39.89B | $17.96B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $137.55 |
52-Week Low | $278.09 | $76.08 |
Enterprise Value | $38.15B | $19.54B |
Dividend Yield | — | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CF Industries (CF) trades at $116.92, up 2.54% today, with strong bullish momentum from earnings beats and a 20% dividend increase announced July 8, 2026. The stock shows robust fundamentals with a P/E of 10.53 and ROE of 34.74%, while technical indicators signal bullish moving averages but overbought RSI levels near 76. Revenue growth rebounded to $7.08B in 2025 after a dip, supported by firm nitrogen demand.
Outlook remains positive with a consensus price target of $126.67, though risks include rising natural gas costs pressuring margins. The stock offers value and income appeal, but investors should monitor input cost trends and Q2 2026 earnings against expectations of $5.71 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About CF Industries Holdings, Inc.
CF Industries is a leading producer and distributor of nitrogen fertilizers. The company operates seven nitrogen facilities in North America and holds joint venture interests in further production capacity in the United Kingdom and Trinidad and Tobago. CF makes nitrogen primarily using low-cost U.S. natural gas as its feedstock, making CF one of the lowest-cost nitrogen producers globally.
Read more on CF →
